PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-184.01%
Negative net income growth while Biotechnology median is -3.48%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
-9.94%
D&A shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
-368.86%
Deferred tax shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
368.86%
SBC growth of 368.86% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
55.40%
Working capital of 55.40% while Biotechnology median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
252.95%
AP growth of 252.95% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
-12.95%
Other WC usage shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
200.11%
Growth of 200.11% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
-85.28%
Negative CFO growth while Biotechnology median is -1.64%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
80.16%
CapEx growth of 80.16% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.16%
Investing flow of 80.16% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
54.75%
Debt repayment growth of 54.75% while Biotechnology median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
-0.41%
We reduce issuance yoy while Biotechnology median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.